Compare TORM plc (TRMD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TORM plc vs 10X Genomics Inc — how do they compare? TORM plc trades at $29.89 (market cap $2.99B), while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and TORM plc pays a 9.62% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TRMD | TXG | |
|---|---|---|
Market Cap | $2.99B | $5.48B |
Sector | Technology | Health |
52-Week High | $34.87 | $45.80 |
52-Week Low | $17.50 | $11.34 |
Enterprise Value | $3.88B | $5.02B |
Dividend Yield | 9.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TRMD trades at $29.08, up 2.21% today, with a bullish technical signal from moving averages. The company reported strong 2025 results with $1.34B revenue and $285.3M net income, though recent Q1 2026 EPS missed expectations. Valuation ratios appear attractive with a P/E of 8.54 and P/S of 2.08. Recent news highlights strong cash generation and a potential merger with Hafnia.
The outlook is positive with 100% analyst buy ratings and a near 9% dividend yield. Key risks include earnings volatility and market exposure, but disciplined capital allocation and high profitability margins support upside potential.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
